ADPT Adaptive Biotechnologies Corp
Company Analysis
Latest News
🟢 Adaptive Biotechnologies Surges 10.29% as Investors Cheer Progress on Unit Separation at Morgan Stanley Fireside Chat
Adaptive Biotechnologies is trading at $27.33 (+10.29%) today. - The surge is driven by investor enthusiasm following management's updates at the Morgan...
🟢 Adaptive Biotechnologies is trading 4.68% up today possibly linked to Morgan Stanley conference appearance
Adaptive Biotechnologies is trading 4.68% up now at $25.94, with investor interest possibly supported by its upcoming Morgan Stanley healthcare conference...
🔴 Adaptive Biotechnologies is trading 5% down in pre-market
Adaptive Biotechnologies is trading 5.28% down at $22.95, after falling from the September 10 close of $24.23, with no clear catalyst identified for September...
🟢 Adaptive Biotechnologies is trading 6.4% up in pre-market with no clear catalyst identified
Adaptive Biotechnologies is trading at $25.99, up 6.4%, with no clear catalyst identified. - The stock rose from its September 9 close of $24.42; no fresh...
🟢 Adaptive Biotechnologies is trading 4.38% up in pre-market while immediate catalyst remains unclear
Adaptive Biotechnologies is trading at $26.01 (+4.38%) in pre-market, while the immediate catalyst remains unclear. - No new company-specific announcement or...
🔴 Adaptive Biotechnologies is trading 4.5% down today
Adaptive Biotechnologies is trading 4.45% down at $24.07 amid broader market weakness, though no definitive catalyst has been identified. • The Dow Jones is...
Adaptive Biotechnologies Lands $18.9M Investment, Driven by Improving Profitability
Freestone Grove Partners LP acquired a new stake in Adaptive Biotechnologies Corp. The institutional investor purchased 881,688 shares. This transaction is...
🔴 Adaptive Biotechnologies falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Adaptive Biotechnologies rises 4.5% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Adaptive Biotechnologies is trading 5.9% up in pre-market with no clear company-specific catalyst
Adaptive Biotechnologies is trading 5.9% up at $26.00, with no clear company-specific announcement identified for August 19, 2026. - The investor-relations...
🟢 Adaptive Biotechnologies is trading 4.01% up today
Adaptive Biotechnologies is trading 4.01% up at $25.93, but no clear company-specific announcement dated August 10, 2026 was identified. - Recent reporting...
🟢 Adaptive Biotechnologies is trading 4.13% up today as XBI gains 2.09%
Adaptive Biotechnologies is trading 4.13% higher at $24.57, with broader biotech-sector strength providing the clearest available explanation. - XBI is up...
🔴 Adaptive Biotechnologies is trading 4.19% down today with no clear catalyst identified
Adaptive Biotechnologies is trading 4.19% down at $23.57, with no clear company-specific catalyst identified on August 6, 2026. - Its latest major event was...
🔴 Adaptive Biotechnologies is trading 4.4% down in pre-market — no clear catalyst identified
Adaptive Biotechnologies is trading 4.4% down at $23.51 in pre-market, with no clear direct catalyst identified. - It closed at $24.60 on August 5; no fresh...
🟢 Adaptive Biotechnologies is trading 4.1% up today on MRD growth and raised guidance
Adaptive Biotechnologies is trading 4.1% up at $24.05 as investors continue to respond to its July 29 earnings report, which featured strong MRD revenue growth...
🟢 Adaptive Biotechnologies is trading 4.3% up today on MRD growth and raised guidance
Adaptive Biotechnologies is trading 4.3% up today at $23.55 as investors focus on the company’s stronger MRD revenue trajectory and raised full-year...
🟢 Adaptive Biotechnologies is trading 4.2% up today after strong Q2 results and raised MRD revenue guidance
Adaptive Biotechnologies is trading at $23.51 (4.2% up) after reporting strong second-quarter results and raising its full-year MRD revenue guidance. •...
🔴 Adaptive Biotechnologies is trading 4.7% down today on wider-than-expected GAAP loss despite raised guidance
Adaptive Biotechnologies is trading at $21.51 (4.7% down) in pre-market after reporting a wider-than-expected GAAP loss per share in its Q2 2026 earnings...
Adaptive Biotechnologies Corp Q2 2026 Earnings Preview: What Analysts Expect on July 29, 2026
Adaptive Biotechnologies Corp is projected to report Q2 2026 revenue of $66.27 million and a consensus EPS loss of $0.13, with shares currently trading at...
🔴 Adaptive Biotechnologies is trading 4.8% down today without a clear catalyst
Adaptive Biotechnologies is trading 4.8% down at $21.45 following a quiet news day with no fresh company-specific headlines or earnings releases linked to the...